Psoriasis is a chronic inflammatory disease affecting over 8 million Americans. Importantly, patients
with psoriasis are at an increased risk of developing atherosclerosis, coronary artery disease, and myocardial
infarctions. Several studies have suggested that psoriasis may be an independent risk factor for cardiovascular
disease given their shared inflammatory properties and pathogenic similarities. Epicardial fat is also linked to
cardiovascular disease and may be an independent risk factor for atherosclerosis. It has been proposed that measuring
epicardial fat tissue may serve as a useful subclinical measure of cardiovascular disease in psoriasis patients.
Echocardiography has been increasingly adopted as an accurate, minimally invasive, and cost-effective
measure of determining the volume and thickness of epicardial fat. Using echocardiographic measures of epicardial
fat thickness as a marker of cardiovascular disease and therapeutic target in psoriasis patients may provide
clinicians with a means to better manage and hopefully prevent deleterious downstream effects.